Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 9/20 | 0.45 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | YAP1 | P46937 | 1/20 | 0.42 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12947420 | 0.86 | SLC9A1 (0.53) | GRM5GRM2OPRL1ACKR3 | |
| SCHEMBL31196623 | 0.81 | OPRL1 (0.53) | GRM2OPRL1ALDH1A1 | |
| SCHEMBL20438978 | 0.75 | SMN1; SMN2 (0.59) | ALDH1A1 | |
| SCHEMBL28021482 | 0.73 | GRM2 (0.40) | GRM2OPRL1 | |
| SCHEMBL1545147 | 0.73 | ACHE (0.61) | — | |
| SCHEMBL434354 | 0.73 | OPRL1 (0.57) | GRM2OPRL1ALDH1A1 | |
| SCHEMBL4975027 | 0.72 | GRM2 (0.47) | GRM2OPRL1ACKR3 | |
| SCHEMBL23780216 | 0.72 | HTR2C (0.48) | ALDH1A1HTTYAP1TEAD4 | |
| SCHEMBL21456015 | 0.72 | NPC1 (0.64) | ALDH1A1NPC1HTTRAB9A | |
| SCHEMBL5019341 | 0.72 | OPRL1 (0.50) | GRM2OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234973-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-07-02 | — | — | EP | disclosed |
| EP-2234973-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-07-02 | — | — | EP | disclosed |
| US-8569495-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-10-29 | — | — | US | disclosed |
| US-8569495-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-10-29 | — | — | US | disclosed |
| US-8569495-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-10-29 | — | — | US | disclosed |
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| EP-2234973-A1 | ANTHELMINTIC AGENTS AND THEIR USE | Intervet International B.V. (NL) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077527-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077527-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | GRM5 1911/4885GRM2 4124/4885OPRL1 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.